Stockscreener 앱 받기
3.465
16.71%
-0.695
시간 외 거래:
3.49
0.025
+0.72%
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com South Africa
Director Hershberg sells $125k in Recursion Pharmaceuticals stock - Investing.com
Director Hershberg sells $125k in Recursion Pharmaceuticals stock By Investing.com - Investing.com UK
Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each. - Stock Titan
A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX). - Stock Titan
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
Recursion Pharmaceuticals Director Hershberg to Sell 25,000 Shares via Option Exercise - Kalkine Media
Recursion Pharmaceuticals, Inc.Class A Common Stock (Nasdaq:RXRX) Stock Quote - FinancialContent
A $0-per-share award brings Zavain Dar's direct Recursion (RXRX) holdings to 245,371 shares. - Stock Titan
Dean Y. Li receives 3,378 Recursion (RXRX) shares under its Outside Director Compensation Policy. - Stock Titan
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - Investing.com
Recursion Pharma CEO Najat Khan sells $78,822 in stock - Investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Quiver Quantitative
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
$Recursion Pharmaceuticals (RXRX.US)$ - Moomoo
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - The Globe and Mail
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? - Eastern Progress
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals director Blake Borgeson sells $100,200 in stock By Investing.com - Investing.com Canada
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake - Moomoo
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Pipeline - Quiver Quantitative
Recursion (NASDAQ: RXRX) director sells 30,000 shares in planned trade - Stock Titan
RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn - StocksToTrade
RXRX | Recursion Pharmaceuticals, Inc. Class FinancialsRevenue Breakdown - Quiver Quantitative
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Ex-Recursion (NASDAQ: RXRX) director plans new sale after 340K-share June trade - Stock Titan
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
3.09%
자본화:
|
볼륨(24시간):